Breaking News Instant updates and real-time market news.

VRX

Ticker changed BHC

$15.44

-0.35 (-2.22%)

07:05
04/09/18
04/09
07:05
04/09/18
07:05

Ortho Dermatologics: JAAD publishes results of Phase trials of DUOBRII

Ortho Dermatologics, a division of Valeant Pharmaceuticals, announced that the Journal of the American Academy of Dermatology published for the first time positive results from two Phase 3, multicenter, randomized, double-blind clinical trials (Studies 1 and 2) to assess the safety and efficacy of DUOBRIITM lotion in the treatment of plaque psoriasis.2 Studies 1 and 2, which enrolled a total of 418 patients, showed DUOBRII was consistently more effective than vehicle in achieving treatment success (defined as those with at least a two-grade improvement from baseline in an Investigator Global Assessment score, and 'clear' or 'almost clear' skin), demonstrating statistically significant superiority by week four (in Study 1) and week two (in Study 2). At week eight, 35.8% (Study 1) and 45.3% (Study 2) had achieved the primary efficacy outcome, compared to 7% and 12.5% on vehicle. The majority of patients maintained treatment success over the four-week post treatment period. DUOBRII was also superior in reducing psoriasis signs and symptoms and body surface area affected compared to vehicle. In addition, DUOBRII showed significant reductions in the severity of the clinical signs of psoriasis. The most common treatment-related adverse events were contact dermatitis (6.3%), application site pain (2.6%) and pruritus (2.2%).

  • 08

    May

  • 13

    May

  • 18

    Jun

  • 27

    Aug

VRX Ticker changed BHC
$15.44

-0.35 (-2.22%)

03/21/18
DBAB
03/21/18
NO CHANGE
Target $20
DBAB
Buy
Deutsche Bank continues to like risk/reward for Valeant shares
Valeant Pharmaceuticals could get more credit for its dermatology pipeline over time as it discloses more details on assets, secures approvals, and executes on launches, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He notes that one key difference between Valeant's longer-term outlook and his model is sales potential for the dermatology business. Management believes it can double sales from 2018-2022 to greater than $1B while Gilbert's estimates are much lower at $600M, likely due to lower pipeline contribution. He believes success in dermatology would represent "significant upside" to his current price target of $20. The analyst continues to like the risk/reward for the stock and maintains a Buy rating on Valeant.
04/06/18
MZHO
04/06/18
UPGRADE
Target $15
MZHO
Neutral
Valeant upgraded to Neutral from Underperform at Mizuho
Mizuho analyst Irina Koffler upgraded Valeant to Neutral and raised its price target to $15 from $10. Koffler sees a lack of near-term sell catalysts and views 2018 guidance as achievable.
04/06/18
MZHO
04/06/18
UPGRADE
Target $15
MZHO
Neutral
Mizuho upgrades Valeant to Neutral on lack of negative catalysts
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals to Neutral from Underperform and raised her price target for the shares to $15 from $10. The drugmaker closed yesterday at $15.79. The analyst, while remaining concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." Further, she views the company's 2018 guidance as achievable.
04/06/18
04/06/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Valeant (VRX) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler saying while she remains concerned about Valeant's return to revenue growth, sees no near-term "sell catalysts." 2. Patterson Companies (PDCO) upgraded to Buy from Hold at Craig-Hallum with analyst Kevin Ellich saying that his sum-of-parts analysis suggests the company could unlock value by splitting its dental and animal health businesses. 3. Prologis (PLD) and AvalonBay (AVB) were upgraded to Buy from Neutral at Citi. 4. Universal Display (OLED) upgraded to Outperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying with the shares down 41% year-to-date, the stock is oversold and the risks are fully priced in. 5. Halyard Health (HYH) upgraded to Overweight from Sector Weight at KeyBanc with analyst Matthew Mishan saying he sees the company's earnings growth accelerating and valuation re-rating following the sale of its Surgical & Infection Prevention unit. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$284.67

2.87 (1.02%)

, SPX

S&P 500

$0.00

(0.00%)

13:19
08/16/18
08/16
13:19
08/16/18
13:19
Periodicals
U.S. and China to hold lower-level trade talks later in August, Reuters says »

A Chinese delegation …

SPY

SPDR S&P 500 ETF Trust

$284.67

2.87 (1.02%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:19
08/16/18
08/16
13:19
08/16/18
13:19
Hot Stocks
Breaking Hot Stocks news story  »

Rosehill Resources Inc…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/16/18
08/16
13:17
08/16/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/16/18
08/16
13:16
08/16/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRP

TransCanada

$43.81

0.04 (0.09%)

13:13
08/16/18
08/16
13:13
08/16/18
13:13
Periodicals
Federal judge orders review of Keystone XL oil pipeline, Reuters reports »

In the latest setback for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$23.39

0.92 (4.09%)

, MYL

Mylan

$37.94

0.12 (0.32%)

13:05
08/16/18
08/16
13:05
08/16/18
13:05
Hot Stocks
Teva granted FDA approval of first generic version of EpiPen »

The U.S. Food and Drug…

TEVA

Teva

$23.39

0.92 (4.09%)

MYL

Mylan

$37.94

0.12 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 10

    Sep

  • 16

    Sep

  • 13

    Nov

GOOG

Alphabet

$1,223.00

9.35 (0.77%)

, GOOGL

Alphabet Class A

$1,239.00

6.7 (0.54%)

13:05
08/16/18
08/16
13:05
08/16/18
13:05
Periodicals
Google workers upset about company making censored engine for China, NYT says »

Hundreds of Google…

GOOG

Alphabet

$1,223.00

9.35 (0.77%)

GOOGL

Alphabet Class A

$1,239.00

6.7 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

13:04
08/16/18
08/16
13:04
08/16/18
13:04
Conference/Events
CFTC to hold a podcast on Agriculture Block Trade Analysis »

Dave Amato, of the U.S.…

HAFC

Hanmi Financial

$25.70

0.4 (1.58%)

13:04
08/16/18
08/16
13:04
08/16/18
13:04
Hot Stocks
Hanmi Financial announces receipt of all regulatory approvals for SWNB merger »

Hanmi Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

CLF

Cleveland-Cliffs

$9.89

0.05 (0.51%)

13:00
08/16/18
08/16
13:00
08/16/18
13:00
Options
Repeat call spreads in Cleveland Cliffs »

Repeat call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

NWBI

Northwest Bancshares

$18.31

0.12 (0.66%)

13:00
08/16/18
08/16
13:00
08/16/18
13:00
Hot Stocks
Northwest Bancshares chairman William Wagner sells over 64K shares »

Northwest Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$23.47

1 (4.45%)

, MYL

Mylan

$37.84

0.02 (0.05%)

12:57
08/16/18
08/16
12:57
08/16/18
12:57
Hot Stocks
Teva rises, Mylan dips after FDA reported to approve first generic EpiPen »

Shares of Mylan (MYL)…

TEVA

Teva

$23.47

1 (4.45%)

MYL

Mylan

$37.84

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 10

    Sep

  • 16

    Sep

  • 13

    Nov

MYL

Mylan

$37.85

0.03 (0.08%)

, TEVA

Teva

$23.45

0.975 (4.34%)

12:53
08/16/18
08/16
12:53
08/16/18
12:53
Periodicals
Breaking Periodicals news story on Mylan, Teva »

FDA approves Teva generic…

MYL

Mylan

$37.85

0.03 (0.08%)

TEVA

Teva

$23.45

0.975 (4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 10

    Sep

  • 16

    Sep

  • 13

    Nov

DE

Deere

$137.51

1.81 (1.33%)

12:51
08/16/18
08/16
12:51
08/16/18
12:51
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

NVDA

Nvidia

$260.13

1.15 (0.44%)

, AMAT

Applied Materials

$47.71

0.22 (0.46%)

12:51
08/16/18
08/16
12:51
08/16/18
12:51
Earnings
Notable companies reporting after market close »

Notable companies…

NVDA

Nvidia

$260.13

1.15 (0.44%)

AMAT

Applied Materials

$47.71

0.22 (0.46%)

JWN

Nordstrom

$51.81

-0.05 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

ADM

Archer Daniels

$50.05

0.62 (1.25%)

12:45
08/16/18
08/16
12:45
08/16/18
12:45
Recommendations
Archer Daniels analyst commentary  »

Archer Daniels price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

GOOG

Alphabet

$1,225.60

11.95 (0.98%)

, GOOGL

Alphabet Class A

$1,241.50

9.2 (0.75%)

12:38
08/16/18
08/16
12:38
08/16/18
12:38
Periodicals
Google preparing to launch display-equipped speaker for holiday season, NAR says »

Google (GOOGL) is…

GOOG

Alphabet

$1,225.60

11.95 (0.98%)

GOOGL

Alphabet Class A

$1,241.50

9.2 (0.75%)

AMZN

Amazon.com

$1,901.56

20.16 (1.07%)

BABA

Alibaba

$175.08

5.28 (3.11%)

AAPL

Apple

$213.46

3.18 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 22

    Aug

  • 23

    Aug

  • 10

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

SPY

SPDR S&P 500 ETF Trust

$285.01

3.21 (1.14%)

, SPX

S&P 500

$0.00

(0.00%)

12:33
08/16/18
08/16
12:33
08/16/18
12:33
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Mnuchin says U.S.…

SPY

SPDR S&P 500 ETF Trust

$285.01

3.21 (1.14%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$345.54

13.81 (4.16%)

12:32
08/16/18
08/16
12:32
08/16/18
12:32
Hot Stocks
Boeing to acquire Millennium Space Systems, terms not disclosed »

Boeing announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWH

MSCI Hong Kong Index

$23.83

0.17 (0.72%)

12:30
08/16/18
08/16
12:30
08/16/18
12:30
Options
One day option play opened in iShares MSCI Hong Kong Fund »

One day option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/16/18
08/16
12:17
08/16/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
08/16/18
08/16
12:16
08/16/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
08/16/18
08/16
12:15
08/16/18
12:15
General news
Atlanta Fed's Q3 GPNow estimate was held at 4.3% »

Atlanta Fed's Q3…

CMG

Chipotle

$525.43

-0.44 (-0.08%)

12:14
08/16/18
08/16
12:14
08/16/18
12:14
Periodicals
Chipotle finds cause of foodborne illness at Ohio location, CNBC says »

Chipotle said that tests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

TIF

Tiffany

$127.95

2.23 (1.77%)

, BABA

Alibaba

$175.17

5.37 (3.16%)

12:13
08/16/18
08/16
12:13
08/16/18
12:13
Periodicals
Tiffany to sell on Alibaba's 'Luxury Pavilion' platform on Tmall, Axios reports »

Tiffany & Co (TIF)…

TIF

Tiffany

$127.95

2.23 (1.77%)

BABA

Alibaba

$175.17

5.37 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 28

    Aug

  • 10

    Sep

  • 12

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.